NCT02829918View on ClinicalTrials.gov

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 5, 2016

Primary Completion Date

March 27, 2019

Study Completion Date

May 24, 2023

Conditions
Biliary Tract CancerBiliary Tract Neoplasms
Interventions
DRUG

Nivolumab

Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.

Trial Locations (3)

30322

Emory University Winship Cancer Institute, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

91010

City of Hope Cancer Center, Duarte

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER